Laurent Pharmaceuticals featured in BioCentury Magazine

15 September 2015

Laurent Pharmaceuticals Inc. announced today that the LAU-7b program addressing aberrant inflammation is featured in the September 14th issue of BioCentury, one of...

Read More

Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis

15 June 2015

LAU-7b is safe and well tolerated by adult Cystic Fibrosis (CF) patientsThe pharmacokinetic profile fully achieved the protocol dose selection rationaleStudy...

Read More


Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021